AF
ESPR

Advisornet Financial’s Esperion Therapeutics ESPR Stock Holding History

Advisornet Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-95
Closed – – 1942
2022
Q1 		$0 Hold
95
– – ﹤0.01% 2040
2021
Q4 		$0 Buy
+95
New +$761 ﹤0.01% 2061
2020
Q2 		– Sell
-100
Closed -$3K – 1808
2020
Q1 		$3K Hold
100
– – ﹤0.01% 1508
2019
Q4 		$6K Hold
100
– – ﹤0.01% 1494
2019
Q3 		$4K Hold
100
– – ﹤0.01% 1591
2019
Q2 		$5K Buy
+100
New +$4.7K ﹤0.01% 1381

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Advisornet Financial's ESPR Position: Q2 2022 in Review

Advisornet Financial sold out of Esperion Therapeutics (ESPR) in Q2 2022, closing a stake of 95 shares.

Advisornet Financial first reported a position in ESPR in Q2 2019 and held it in 6 quarters. The position peaked at $6K in Q4 2019. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

  • Advisornet Financial reported no remaining Esperion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Advisornet Financial sold 95 Esperion Therapeutics shares in Q2 2022.
  • Advisornet Financial first reported a position in Esperion Therapeutics in Q2 2019 and held it in 6 quarters.
  • Advisornet Financial's Esperion Therapeutics position peaked at $6K in Q4 2019.
  • 136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Advisornet Financial's 13F filing for Q2 2022, filed 7 Jul 2022.